Travere Therapeutics
TVTX
Travere Therapeutics (TVTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.37
- EPS estimate
- −$0.13
- EPS surprise
- −174.68%
- Revenue surprise
- +7.83%
- Revenue
- $169.6M
- Revenue estimate
- $157.3M
- Reported
- Aug 4, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | −$0.13 | −$0.37 | −174.68% | $169.6M | SEC |
| Q1 2026 | May 4, 2026 | −$0.24 | −$0.40 | −65.29% | $127.2M | SEC |
| Q4 2025 | Feb 19, 2026 | $0.00 | $0.03 | +1150.00% | $129.7M | SEC |
| Q3 2025 | Oct 30, 2025 | −$0.30 | $0.28 | +192.20% | $164.9M | SEC |
| Q2 2025 | Aug 6, 2025 | −$0.31 | −$0.14 | +55.09% | $94.8M | SEC |
| Q1 2025 | May 1, 2025 | −$0.57 | −$0.47 | +17.11% | $75.9M | SEC |
| Q4 2024 | Feb 20, 2025 | −$0.56 | −$0.73 | −29.89% | $73.5M | SEC |
| Q3 2024 | Oct 31, 2024 | −$0.67 | −$0.70 | −4.62% | $62.9M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.79 | −$0.91 | −15.04% | $54.1M | SEC |
| Q1 2024 | May 6, 2024 | −$0.96 | −$1.76 | −83.60% | $41.4M | SEC |
| Q4 2023 | Feb 15, 2024 | −$1.16 | −$1.18 | −1.94% | $45.1M | SEC |
| Q3 2023 | Nov 7, 2023 | −$1.06 | $1.97 | +285.08% | $33.9M | SEC |
| Q2 2023 | Aug 3, 2023 | −$1.09 | −$1.13 | −3.80% | $57.0M | SEC |
| Q1 2023 | May 4, 2023 | −$1.20 | −$1.27 | −5.77% | $57.0M | SEC |
| Q4 2022 | Feb 23, 2023 | −$1.13 | −$1.03 | +9.17% | $55.9M | SEC |
| Q3 2022 | Oct 27, 2022 | −$0.95 | −$1.09 | −15.00% | $53.5M | SEC |
| Q2 2022 | Aug 4, 2022 | −$0.94 | −$1.05 | −11.83% | $51.0M | SEC |
| Q1 2022 | May 5, 2022 | −$0.87 | −$1.20 | −37.93% | $48.5M | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.74 | −$0.84 | −14.18% | $57.2M | SEC |
| Q3 2021 | Oct 28, 2021 | −$0.56 | −$0.59 | −5.04% | $68.2M | SEC |
Quarterly revenue
Frequently asked questions
When did Travere Therapeutics (TVTX) last report earnings?
Travere Therapeutics last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did TVTX beat earnings estimates?
No. Travere Therapeutics reported EPS of −$0.37 for Q2 2026 against a −$0.13 estimate — a 174.68% miss.
How much revenue did TVTX report last quarter?
Travere Therapeutics reported $169.6M in revenue for Q2 2026, against a consensus estimate of $157.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.